Quarterly ResultMay 11, 2026, 04:07 PM
Metagenomi Q1 Net Loss $23.1M; MGX-001 IND on track for 4Q 2026
AI Summary
Metagenomi Therapeutics reported a net loss of $23.1 million for the first quarter ended March 31, 2026, an improvement from $25.0 million in the comparable period of 2025. The company maintained a strong cash position of $140.2 million, providing a runway anticipated to support operations through Q4 2027. Key business updates include the MGX-001 program for hemophilia A remaining on track for regulatory submission in Q4 2026 and the initiation of clinical trials in 2027, alongside a publication highlighting their proprietary compact CRISPR nuclease, MG119-28.
Key Highlights
- Cash, cash equivalents, and available-for-sale marketable securities were $140.2 million as of March 31, 2026.
- Cash runway is anticipated to support operations through Q4 2027.
- MGX-001 program for hemophilia A remains on track for regulatory submission, including an IND, in Q4 2026.
- Clinical trials for MGX-001 are expected to initiate in 2027, subject to regulatory clearance.
- Research and development expenses were $19.3 million for Q1 2026, down from $25.1 million in Q1 2025.
- General and administrative expenses were $6.5 million for Q1 2026, down from $6.8 million in Q1 2025.
- Net loss for Q1 2026 was $23.1 million, compared to $25.0 million for Q1 2025.
- Publication in Nature Structural & Molecular Biology highlighted MG119-28, a compact CRISPR nuclease with enhanced editing efficiency.